GFO Kliniken Troisdorf, Betriebsstaette St. Johannes
- Address
- lock Available on a paid plan
GFO Kliniken Troisdorf, Betriebsstaette St. Johannes - Stroke Prevention Research
GFO Kliniken Troisdorf, Betriebsstaette St. Johannes is actively engaged in advanced clinical research focused on cerebrovascular disease management and prevention. The center specializes in investigating innovative therapeutic approaches for patients who have experienced acute neurological events, with particular emphasis on preventing recurrent ischemic episodes.
- Prevention of secondary ischemic stroke following acute non-cardioembolic stroke
- Management of high-risk transient ischemic attack (TIA) patients
- Novel anticoagulation therapies including FXIa inhibitors
The facility participates in cutting-edge trials evaluating asundexian, an oral Factor XIa inhibitor, as part of comprehensive stroke prevention strategies. Their research focuses on assessing both the efficacy of novel antiplatelet and anticoagulation combinations in reducing recurrent ischemic stroke risk while carefully monitoring safety outcomes, particularly regarding major bleeding events. This dual emphasis on efficacy and safety reflects the center's commitment to developing optimal therapeutic strategies for patients recovering from acute non-cardioembolic ischemic stroke and high-risk TIA events.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in GFO Kliniken Troisdorf, Betriebsstaette St. Johannes
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Asundexian for Ischemic Stroke Prevention in Adults Post-Acute Non-Cardioembolic Stroke or High-Risk TIA | Bayer AG | Phase III | Not Recruiting | Jan 2023 | Oct 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asundexian | 1 | Unknown | 2023-01-18 | 2023-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.